NCT04545749View on ClinicalTrials.gov

A Study to Evaluate the Safety, Tolerability, and Immunogenicity of UB-612 COVID-19 Vaccine

PHASE1CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

September 25, 2020

Primary Completion Date

January 18, 2021

Study Completion Date

May 24, 2021

Conditions
COVID-19
Interventions
BIOLOGICAL

UB-612

UB-612 is a proprietary high-precision designer S1-RBD-protein based vaccine incorporating a Th/CTL epitope peptide pool which could bind to human MHC-I and MHC-II to activate T cells.

Trial Locations (1)

404

China Medical University Hospital, Taichung

All Listed Sponsors
collaborator

Vaxxinity, Inc.

INDUSTRY

lead

United Biomedical Inc., Asia

INDUSTRY

NCT04545749 - A Study to Evaluate the Safety, Tolerability, and Immunogenicity of UB-612 COVID-19 Vaccine | Biotech Hunter | Biotech Hunter